Swiss National Bank Cytom X Therapeutics, Inc. Transaction History

Swiss National Bank

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$3.87 - $7.39 $449,694 - $858,718	-116,200 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$6.6 - $9.0 $146,520 - $199,800	22,200 Added 23.62%	116,200 $898,000
Q4 2020 Feb 05, 2021	BUY	$6.47 - $7.9 $17,469 - $21,330	2,700 Added 2.96%	94,000 $616,000
Q2 2020 Aug 05, 2020	BUY	$7.4 - $14.64 $32,560 - $64,416	4,400 Added 5.06%	91,300 $761,000
Q4 2019 Feb 06, 2020	BUY	$5.17 - $8.91 $15,510 - $26,730	3,000 Added 3.58%	86,900 $722,000
Q2 2019 Aug 02, 2019	BUY	$9.35 - $11.41 $56,100 - $68,460	6,000 Added 7.7%	83,900 $941,000
Q1 2019 May 10, 2019	BUY	$9.5 - $19.16 $22,800 - $45,984	2,400 Added 3.18%	77,900 $837,000
Q4 2018 Feb 13, 2019	BUY	$12.69 - $18.61 $34,263 - $50,247	2,700 Added 3.71%	75,500 $1.14 Million
Q3 2018 Nov 08, 2018	BUY	$18.04 - $26.41 $227,304 - $332,766	12,600 Added 20.93%	72,800 $1.35 Million
Q2 2018 Aug 09, 2018	BUY	$21.38 - $29.68 $525,948 - $730,128	24,600 Added 69.1%	60,200 $1.38 Million
Q1 2018 May 04, 2018	BUY	$21.76 - $34.22 $47,872 - $75,284	2,200 Added 6.59%	35,600 $1.01 Million
Q3 2017 Nov 03, 2017	BUY	$13.53 - $18.17 $451,902 - $606,878	33,400	33,400 $607,000

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.